Cooley advised the underwriters on Zymeworks’ $115.0 million follow-on public offering of 11,035,000 common shares at a price to the public of $8.00 per share and pre-funded warrants to purchase 3,340,000 common shares at a price to the public of $7.9999 per pre-funded warrant. This includes 1,875,000 shares issued upon the exercise in full of the underwriters’ option to purchase additional shares. Zymeworks is a clinical-stage biopharmaceutical company developing and commercializing of next-generation multifunctional biotherapeutics. Partners Denny Won, Kristin VanderPas, Charlie Kim and Dave Peinsipp led the Cooley team.